FDA advisers to review ALS drug funded by Ice Bucket Challenge

Österreich Nachrichten Nachrichten

FDA advisers to review ALS drug funded by Ice Bucket Challenge
Österreich Neuesten Nachrichten,Österreich Schlagzeilen
  • 📰 NBCNews
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 86%

FDA advisers to review ALS drug funded by Ice Bucket Challenge.

approved by the FDA for the disease and its symptoms; one has been shown to extend the lives of patients by about three months.

FDA scientists, however, appeared skeptical about the benefits of the drug, saying in the briefing documents that the results of Amylyx's trial were"not robust." It's possible, he said, that a Phase 3 trial could reveal the drug doesn't work as expected, even though the Phase 2 trial showed there was an apparent benefit.

Lynch, of the University of Pennsylvania, said that after reading the FDA documents, a"flat out rejection" of the drug by the agency "would surprise me less than I was predicting last week."

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

NBCNews /  🏆 10. in US

Österreich Neuesten Nachrichten, Österreich Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

FDA skeptical of benefits from experimental ALS drugFDA skeptical of benefits from experimental ALS drugThe drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who’ve joined in pushing the FDA to greenlight the drug.
Weiterlesen »

FDA skeptical of benefits from experimental ALS drugFDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease
Weiterlesen »

FDA Skeptical of Benefits From Experimental ALS DrugFDA Skeptical of Benefits From Experimental ALS DrugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease
Weiterlesen »

FDA skeptical of benefits from experimental ALS drugFDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease.
Weiterlesen »

FDA skeptical of benefits from experimental ALS drugFDA skeptical of benefits from experimental ALS drugThe drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who’ve joined in pushing the FDA to greenlight the drug.
Weiterlesen »

FDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease.
Weiterlesen »



Render Time: 2025-04-05 08:48:15